vorinostat has been researched along with Leukocytopenia in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat was administered at the assigned dosage level (100-400 mg, three times weekly) in a standard 3 + 3 dose escalation design." | 2.90 | A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma. ( Agrawal, A; Baiocchi, R; Blakaj, D; Carrau, R; Diavolitsis, V; Grecula, J; Kang, S; Kumar, B; Kumar, P; Old, MO; Ozer, E; Palettas, M; Pan, Q; Rocco, J; Savvides, P; Teknos, TN; Wei, L, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Teknos, TN | 1 |
| Grecula, J | 1 |
| Agrawal, A | 1 |
| Old, MO | 1 |
| Ozer, E | 1 |
| Carrau, R | 1 |
| Kang, S | 1 |
| Rocco, J | 1 |
| Blakaj, D | 1 |
| Diavolitsis, V | 1 |
| Kumar, B | 1 |
| Kumar, P | 1 |
| Pan, Q | 1 |
| Palettas, M | 1 |
| Wei, L | 1 |
| Baiocchi, R | 1 |
| Savvides, P | 1 |
1 trial available for vorinostat and Leukocytopenia
| Article | Year |
|---|---|
A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.
Topics: Anemia; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Drug Eruptions; Female; Head and Neck N | 2019 |